10,000 Shares in Tempus AI, Inc. (NASDAQ:TEM) Purchased by Congress Wealth Management LLC DE

Congress Wealth Management LLC DE purchased a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,000 shares of the company's stock, valued at approximately $338,000.

Other hedge funds have also made changes to their positions in the company. The Manufacturers Life Insurance Company lifted its stake in Tempus AI by 10.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company's stock worth $1,686,000 after acquiring an additional 2,765 shares in the last quarter. Captrust Financial Advisors acquired a new position in shares of Tempus AI in the 3rd quarter valued at about $2,726,000. NEA Management Company LLC lifted its position in shares of Tempus AI by 17.8% in the third quarter. NEA Management Company LLC now owns 5,385,979 shares of the company's stock worth $304,846,000 after purchasing an additional 813,169 shares in the last quarter. Benjamin Edwards Inc. acquired a new stake in shares of Tempus AI during the third quarter worth approximately $725,000. Finally, Stifel Financial Corp purchased a new position in Tempus AI during the third quarter valued at approximately $218,000. Hedge funds and other institutional investors own 24.22% of the company's stock.

Tempus AI Trading Up 3.1 %

TEM stock traded up $1.47 during midday trading on Wednesday, hitting $48.69. 2,436,452 shares of the company traded hands, compared to its average volume of 5,253,486. Tempus AI, Inc. has a twelve month low of $22.89 and a twelve month high of $91.45. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The business has a 50 day simple moving average of $58.64 and a 200-day simple moving average of $51.56.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Piper Sandler cut their target price on shares of Tempus AI from $70.00 to $55.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Morgan Stanley increased their price objective on Tempus AI from $50.00 to $60.00 and gave the stock an "overweight" rating in a report on Thursday, March 6th. JPMorgan Chase & Co. cut Tempus AI from an "overweight" rating to a "neutral" rating and lifted their price objective for the company from $50.00 to $55.00 in a research report on Tuesday, February 25th. Guggenheim reaffirmed a "buy" rating on shares of Tempus AI in a research report on Tuesday, February 25th. Finally, Loop Capital cut their price target on Tempus AI from $57.00 to $52.00 and set a "buy" rating for the company in a research note on Tuesday, January 14th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $61.18.

Insider Activity at Tempus AI

In related news, Director Jennifer A. Doudna sold 1,320 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $90.00, for a total transaction of $118,800.00. Following the completion of the sale, the director now owns 36,011 shares in the company, valued at $3,240,990. This represents a 3.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO James William Rogers sold 23,030 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $45.97, for a total value of $1,058,689.10. Following the completion of the sale, the chief financial officer now directly owns 164,750 shares in the company, valued at $7,573,557.50. This trade represents a 12.26 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,598,969 shares of company stock worth $317,194,162.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.